Stéphane Bancel is the Chief Executive Officer of Moderna, Inc., a leading biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. Born in Marseille, France, Bancel holds a Master of Engineering degree from École Centrale Paris and an MBA from Harvard Business School. Before joining Moderna in 2011, he had a distinguished career in the life sciences industry, including serving as CEO of the French diagnostics company bioMérieux and holding various leadership positions at Eli Lilly and Company. Under Bancel's leadership, Moderna has grown from a small startup to a major player in the biotechnology industry. He has been instrumental in guiding the company through its research and development phases, securing significant funding, and navigating the complex regulatory landscape. One of his most notable achievements was overseeing the rapid development and deployment of Moderna's COVID-19 vaccine, which played a crucial role in the global fight against the pandemic. Bancel's strategic vision and commitment to innovation have been key factors in Moderna's success, as evidenced by the company's successful IPO in 2018 and its subsequent growth. As CEO, Bancel continues to lead Moderna's efforts to expand its mRNA platform and develop new treatments for a wide range of diseases. He is known for his hands-on approach and his ability to foster a collaborative and innovative work environment. Bancel's leadership has not only propelled Moderna to the forefront of the biotechnology industry but has also positioned the company as a leader in the development of groundbreaking medical technologies.